Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen.

被引：0
|
作者：
Garber, JE
Halabi, S
Kaplan, E
Edge, S
Dressler, L
Paskett, E
Berliner, N
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Duke Univ, Durham, NC 27706 USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Yale Univ, Sch Med, New Haven, CT 06520 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6S / 6S
页数：1
相关论文
共 50 条
  • [31] Variant Alleles in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) or Methylenetetrahydrofolate Reductase (MTHFR) and risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients
    Falvella, F. S.
    Cremolini, C.
    Miceli, R.
    Nichetti, F.
    Cheli, S.
    Antoniotti, C.
    Infante, G.
    Martinetti, A.
    Loupakis, F.
    Di Bartolomeo, M.
    Marmorino, F.
    Sottotetti, E.
    Bossi, I.
    Berenato, R.
    Caporale, M.
    Niger, M.
    Colombo, A.
    De Braud, F.
    Clementi, E.
    Pietrantonio, F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S83 - S84
  • [32] Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen (vol 96, pg 1762, 2004)
    McCaskill-Stevens
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01): : 71 - 71
  • [33] Factor V Leiden but not prothrombin 20210A mutation associated with massive fatal thromboembolic events.
    Sanders, ME
    Rebbeck, TR
    Litzky, LA
    Leonard, DGB
    Pollak, ES
    BLOOD, 2002, 100 (11) : 273A - 274A
  • [34] Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes
    Ragaz, J
    Coldman, A
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2018 - 2024
  • [35] CARDIAC AND THROMBOEMBOLIC MORBIDITY AMONG POSTMENOPAUSAL WOMEN WITH EARLY-STAGE BREAST-CANCER IN A RANDOMIZED TRIAL OF ADJUVANT TAMOXIFEN
    RUTQVIST, LE
    MATTSSON, A
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (17) : 1398 - 1406
  • [36] The tamoxifen paradoxinfluence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer
    Kyvernitakis, I.
    Kostev, K.
    Hadji, P.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (11) : 2557 - 2564
  • [37] A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen.
    Lintermans, A.
    Dieudonne, A-S
    Vanderhaegen, J.
    Henry, N. L.
    Laenen, A.
    Wildiers, H.
    Paridaens, R.
    Christiaens, M-R
    Smeets, A.
    Leunen, K.
    Amant, F.
    Vergote, I.
    Neven, P.
    CANCER RESEARCH, 2011, 71
  • [38] Risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients with single nucleotide polymorphisms (SNPs) in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR)
    Falvella, S.
    Cremolini, C.
    Miceli, R.
    Niger, M.
    Berenato, R.
    Cheli, S.
    Antoniotti, C.
    Nichetti, F.
    Infante, G.
    Caporale, M.
    Martinetti, A.
    Marmorino, F.
    Sottotetti, E.
    Colombo, A.
    Bossi, I.
    Di Bartolomeo, M.
    de Braud, F.
    Clementi, E.
    Loupakis, F.
    Pietrantonio, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 41 - 41
  • [39] PREVALENCE OF INHERITED AND ACQUIRED RISK FACTORS FOR VENOUS THROMBOEMBOLIC (VTE) DISEASE AMONG WOMEN WITH BREAST CANCER TAKING ADJUVANT TAMOXIFEN (TAM)
    Molica, Stefano
    Battaglia, Caterina
    Santoro, Rita
    Mirabelli, Rosanna
    Squillace, Roberto
    Iannaccaro, Piergiorgio
    Lazzaro, Bonaventura
    Muleo, Gaetano
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [40] Prevalence of Factor V Leiden (FVL, G1691A) and F-II (G20210A) Mutations in Jordanian Atherosclerotic Patients
    Jaradat, Ahmad Q.
    BIOCHEMISTRY MOSCOW-SUPPLEMENT SERIES B-BIOMEDICAL CHEMISTRY, 2023, 17 (04) : 189 - 193
12345